期刊文献+

肾炎康汤治疗慢性肾小球肾炎48例临床观察 被引量:1

下载PDF
导出
摘要 目的:观察肾炎康汤治疗慢性肾小球肾炎(CGN)的临床疗效。方法:将96例CGN患者随机分为2组,对照组48例,口服苯那普利片及常规西药支持对症治疗;治疗组48例,在对照组治疗基础上加服肾炎康汤(主要成分:八仙草、三七、薏苡仁、鹿衔草等)。疗程3月。观察临床疗效;尿蛋白定量、尿红细胞排泄率、血肌酐(Cr);血清转化生长因子β1(TGF-β1)、层黏蛋白(LN)、Ⅳ型胶原(Col-Ⅳ)。结果:治疗组总有效率85.42%,对照组60.42%,2组比较,差异有显著性意义(P<0.05)。治疗后2组尿蛋白定量、Cr均明显下降,与治疗前比较,差异有显著性或非常显著性意义(P<0.05,P<0.01);治疗组较对照组改善更显著,2组治疗后比较,差异有显著性意义(P<0.05)。慢性肾炎患者治疗前后血清TGF-β1、LN、Col-Ⅳ均显著高于正常对照组(P<0.01)。2组治疗后各项指标均明显改善,与治疗前比较,差异有显著性或非常显著性意义(P<0.05,P<0.01);治疗组较对照组改善更显著,2组治疗后比较,差异有显著性或非常显著性意义(P<0.05,P<0.01)。结论:肾炎康汤治疗CGN,能提高临床疗效,保护肾功能,其机理可能与抗肾纤维化作用有关。
出处 《新中医》 CAS 北大核心 2008年第1期32-34,共3页 New Chinese Medicine
  • 相关文献

参考文献6

二级参考文献46

  • 1张明,郭慕依,张秀荣,金惠铭.肾小球系膜增生机制的免疫组化研究[J].中华肾脏病杂志,1995,11(4):208-211. 被引量:16
  • 2于世瀛,贲长恩,杨美娟,赵丽云,白锦雯.清热利湿方药抗肝纤维化的形态学和免疫组织化学定量研究[J].北京中医药大学学报,1997,20(1):28-30. 被引量:32
  • 3王海燕 郑法雷 等.原发性肾小球疾病分型与治疗及诊断标准专题座谈会纪要[J].中华内科杂志,1993,2:131-134.
  • 4Yarnamoto T, Noble NA, Miller DE, et al. Sustained expression of TGF-β1 underlies development of progressive kidney fibrosis. Kidney Int, 1994,45(3) :916 - 927.
  • 5Schafer L, Lorenz T,Daemmrich J, et al. Role of proteinase in renal hypertrophy and matrix accumulation. Nephrpl Dial Transplant, 1995,10(6) :801-807.
  • 6Makino H, Hayashi Y, Shikata K, et al. Urinary detection of type IV collagen and its increase in glomerulonephritis. Res Commun Mol Pathol Pharmacol, 1995,88(2) :215 - 223.
  • 7Fogo AB. Glomerular Hypertension, abnormal glomerular growth, and progression of renal diseases. Kidney Int,2000,75:s15-s21.
  • 8沈庆法.肾病与湿热[J].上海中医药杂志,1983,(3):10-10.
  • 9刘志明.慢性肾炎证治[J].中医杂志,1986,(10):17-17.
  • 10.中药新药临床研究指导原则(第1辑)[M].北京:中华人民共和国卫生部,1993.215.

共引文献1460

同被引文献15

  • 1Nagata M. Podocyte injury and its consequences[ J]. Kidney Int, 2016,89(6) : 1221 - 1230.
  • 2Aizawa K, Takeda S, Tashiro Y,et al. Renoproteetion by continu- ous erythropoietin receptor activator in puromycin aminonucleoside - induced nephrotic syndrome [ J ]. Am J Nephro1,2012,36 ( 5 ) : 419 -426.
  • 3Xie H, Lin HL, Wang N, et al. Inhibition of microRNA - 30a prevents puromycin aminonucleoside -induced podocytic apoptosis by upregulating the glucocorticoid receptor α [ J]. Mol Med Rep, 2015 Oct;12(4) :6043 -6052.
  • 4Yoo TH, Fornoni A. Nonimmunologie targets of immunosuppressive agents in podocytes[J]. Kidney Res Clin Pract, 2015,34 ( 2 ) :69 -75.
  • 5Wharram BL, Goyal M, Wiggins JE, et al. Podocyte depletion causes glomeruloselerosis: diphtheria toxin -induced podocyte de- pletion in rats expressing human diphtheria toxin receptor trans- gene[J]. J Am Soc Nephrol, 2005 ,16(10) :2941 -2952.
  • 6Gao F, Yao M, Shi Y, et al. Notch pathway is involved in high glucose - induced apoptosis in podocytes via Bcl - 2 and p53 path- ways[J]. J Cell Biochem, 2013,114(5) :1029 -1038.
  • 7Liu L, Lin W, Zhang Q. TGF-β induces miR-30d down -reg- ulation and podocyte injury through Smad2/3 and HDAC3 - asso- ciated transcriptional repression [ J ]. J Mol Med( Berl ), 2016,94 (3) :291 -300.
  • 8Wen Y, Zhou P, Liu L, et al. Effect of the knockdown of Cabinl on p53 in glomerular podocyte [ J ]. J Recept Signal Transduct Res, 2016,36(2) :173 - 180.
  • 9Sha WG, Shen L, Zhou L,et al. Down - regulation of miR- 186 con- tributes to podocytes apoptosis in membranous nephropathy[ J ]. Bi- omed Pharmacother, 2015,75:179 - 184.
  • 10Eisenreich A, Langer S, Herlan L, et al. Regulation of podoplanin expression by microRNA - 29b associates with its antiapoptotic effect in angiotensin II- induced injury of human podoc-ytes[ J ].J Hypertens, 2016,34(2) :323 -331.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部